Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings LLC-A (NASDAQ: MDBH) operates a pioneering public venture platform bridging deep technology innovation with capital markets. This news hub provides investors and analysts with essential updates on the company's dual operational focus: its self-clearing broker-dealer platform with integrated intellectual property services, and its technology development arm nurturing early-stage ventures.
Discover real-time information on securities offerings, strategic partnerships, and technology commercialization efforts. The platform serves as a strategic resource for tracking MDBH's role in transforming pre-revenue deep tech concepts into public market opportunities through its unique combination of investment banking services and patent intelligence.
Key updates include developments in IP-driven due diligence, early-stage company financings, and market expansion initiatives. Content is curated to help stakeholders monitor the company's progress in building operational efficiencies while maintaining compliance with public market requirements.
Bookmark this page for ongoing insights into MDB Capital Holdings' community-driven investment model and its impact on emerging technology sectors. Regular updates ensure informed tracking of the company's position at the intersection of venture capital and public market innovation.
MDB Capital Holdings (NASDAQ: MDBH) has scheduled a Zoom webinar for Thursday, November 21, 2024, at 4:30 p.m. Eastern Time to discuss its third quarter 2024 results. CEO Christopher Marlett will lead the presentation, accompanied by management team members, to review recent developments, ongoing initiatives, and anticipated milestones. The company will release detailed financial results before the call. Investors can pre-register for the webinar through a provided link or access it via MDB's investor relations website.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.
Invizyne Technologies (NASDAQ:IZTC), a designer of cell-free, enzyme-based biomanufacturing systems, began trading on Nasdaq on Nov. 13, 2024. The company, founded in 2019, is based on technology developed by UCLA Professor Emeritus James Bowie that enables enzymatic pathways to function outside living cells. CEO Michael Heltzen emphasized the company's ability to overcome traditional cell-based synthetic biology limitations through their next-generation enzymes and biomanufacturing platform, aiming to demonstrate commercial viability through licensing deals and partnerships.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the Nasdaq Capital Market on November 13, 2024, under the ticker symbol 'IZTC'. The company, which focuses on producing commercially important molecules and chemicals for everyday life, expects the offering to close on November 14, 2024, subject to customary closing conditions.
Invizyne Technologies has announced the pricing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share, raising $15 million in gross proceeds. Trading will begin on Nasdaq under ticker 'IZTC' on November 12, 2024. The company granted a 45-day over-allotment option for 281,250 additional shares and will issue 184,375 warrants in a concurrent private placement. Proceeds will fund production expansion, business development, sales and marketing, loan repayment, and working capital. The offering is expected to close on November 13, 2024, with MDB Capital acting as underwriter.
MDB Capital Holdings, (NASDAQ: MDBH) has announced its sponsorship of TCA Venture Group, one of the largest angel investor networks in Southern California. The partnership, which began in August 2024, aims to provide TCA's angel investors with insights into public venture investing and potential future collaboration opportunities.
As part of this initiative, MDB will share deep tech insights and co-host events with TCA. The first joint event is scheduled for October 21, 2024, featuring Lou Basenese, MDB Capital President & Chief Market Strategist, and Dave Berkus, TCA Chairman Emeritus, discussing 'Traditional Venture vs Public Venture'. This virtual event is open to all individual and angel investors.
The sponsorship is expected to support TCA through events across its network and assist portfolio companies with their exit plans. Both organizations express excitement about the collaboration and its potential benefits for entrepreneurs and investors in the innovation industry.
MDB Capital Holdings has announced the record date and expected timing for the IPO of its subsidiary, Invizyne Technologies. The record date for allocation preferences is set for July 22, 2024, with the IPO expected to close and start trading on NASDAQ on or before August 15, 2024. Invizyne, specializing in cell-free, enzyme-based biomanufacturing systems, aims to raise $17.2 million by offering 4,300,000 shares at $4.00 per share. MDB Class A shareholders will have allocation preferences in this IPO, with additional shares potentially available on a pro-rata basis. Interested investors must contact MDB Capital by August 5, 2024, to indicate the number of shares sought.
PatentVest, a leading IP intelligence strategy and law firm, recently published a whitepaper exploring innovations in MASH (Metabolic-Associated Steatohepatitis) diagnostics. The document offers strategic insights into MASH biomarkers and Point of Care (PoC) kits for detecting and monitoring this condition. Key drivers include the recent approval of the MASH drug, Rezdiffra, and an increase in patenting activities. Emerging patent opportunities are identified in non-invasive diagnostic techniques, multi-biomarker tools, and personalized medicine approaches. This whitepaper aims to guide stakeholders in navigating the competitive landscape by leveraging innovation and IP protection. The full report is available on the PatentVest website.
MDB Capital Holdings (NASDAQ: MDBH) has announced a collaboration with Mayo Clinic to develop a small molecule anti-senescence platform. This partnership targets research in longevity and the prevention of age-related diseases by eliminating senescent cells, which are linked to chronic low-grade inflammation and various age-related diseases, including fibrosis. Mayo Clinic's studies have demonstrated the potential of the molecule to significantly reverse fibrosis. The global market for longevity and anti-senescence therapy is projected to reach $45 billion by 2030. Both MDB's CEO, Christopher Marlett, and Mayo Clinic's Dr. Andrew J. Haak expressed enthusiasm about the collaboration's potential to advance patient care.
